Opaleye Management Inc. Contrafect Corp Transaction History

Opaleye Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$3.19 - $4.43 $184,701 - $256,496	-57,900 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.58 - $4.9 $666,238 - $911,890	-186,100 Reduced 76.27%	57,900 $255,000
Q1 2021 May 18, 2021	SELL	$4.46 - $6.68 $874,160 - $1.31 Million	-196,000 Reduced 44.55%	244,000 $1.17 Million
Q4 2020 Feb 12, 2021	BUY	$5.05 - $6.4 $1.08 Million - $1.37 Million	213,873 Added 94.58%	440,000 $2.22 Million
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $1.14 Million - $1.58 Million	226,127 New	226,127 $1.19 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.